Clinical Applications

Imaging in Parkinson's Disease

Volumn , Issue , 2011, Pages

  Poston, Kathleen L ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Atypical parkinsonism; Brain networks; Differential diagnosis; Metabolism imaging; Parkinson's disease; Tremor

Indexed keywords

EID: 84921258570     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195393484.003.0126     Document Type: Chapter

References (104)

1. Antonini, A., K. Kazumata, A. Feigin et al. 1998. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Mov Disord 13:268-274.
2. Antonini, A., K. L. Leenders, P. Vontobel et al. 1997. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 120:2187-2195.
3. Asanuma, K., V. Dhawan, M. Carbon, and D. Eidelberg. 2004. Assessment of disease progression in parkinsonism. J Neurol 251 (Suppl 7): vII4-8.
4. Asenbaum, S., W. Pirker, P. Angelberger et al. 1998. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 105:1213-1228.
5. Bain, P. G. 2009. Dystonic tremor presenting as parkinsonism: Long-term follow-up of SWEDDs. Neurology 72:1443-1445.
6. 123-FP-CIT SPECT scan explorations improves diagnostic accuracy. Mov Disord 21:310-317.
7. Berding, G., P. Odin, D. J. Brooks et al. 2001. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord 16:1014-1022.
8. Blin, J., J. C. Baron, B. Dubois et al. 1990. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 47:747-752.
9. Braak, H., and E. Braak. 2000. Pathoanatomy of Parkinson's disease. J Neurol 247 (Suppl 2): II3-10.
10. Brennan, K. C., E. C. Jurewicz, B. Ford et al. 2002. Is essential tremor predominantly a kinetic or a postural tremor? A clinical and electrophysiological study. Mov Disord 17:313-316.
11. Ceravolo, R., A. Antonini, D. Volterrani et al. 2008. Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study. Movement Disorders 23:2049-2054.
12. Chaudhuri, K. R., M. Buxton-Thomas, V. Dhawan et al. 2005. Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: Clinical follow up study of 13 cases. J Neurol Neurosurg Psychiatry 76:115-117.
13. Christine, C. W., P. A. Starr, P. S. Larson et al. 2009. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73:1662-1669.
14. Cohen, O., S. Pullman, E. Jurewicz et al. 2003. Rest tremor in patients with essential tremor: Prevalence, clinical correlates, and electrophysiologic characteristics. Arch Neurol 60:405-410.
15. De Volder, A. G., J. Francart, C. Laterre et al. 1989. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol 26:239-247.
16. Eckert, T., A. Feigin, D. E. Lewis et al. 2007. Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging. Mov Disord 22:167-173.
17. Eckert, T., and C. Edwards. 2007. The application of network mapping in differential diagnosis of parkinsonian disorders. Clin Neurosci Res 6:359-366.
18. Eckert, T., C. Tang, and D. Eidelberg. 2007. Assessment of the progression of Parkinson's disease: A metabolic network approach. Lancet Neurol 6:926-932.
19. Eckert, T., C. Tang, Y. Ma et al. 2008. Abnormal metabolic networks in atypical parkinsonism. Mov Disord 23:727-733.
20. Eckert, T., A. Barnes, V. Dhawan et al. 2005. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 26:912-921.
21. Eidelberg, D. 2009. Metabolic brain networks in neurodegenerative disorders: A functional imaging approach. Trends Neurosci 32:548-557.
22. Eidelberg, D., J. R. Moeller, K. Kazumata et al. 1997. Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain 120 (Pt 8):1315-1324.
23. Eidelberg, D., J. R. Moeller, T. Ishikawa et al. 1995. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 45:1995-2004.
24. Eidelberg, D., J. R. Moeller, V. Dhawan et al. 1990. The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 5:203-213.
25. Eidelberg, D., J. R. Moeller, V. Dhawan et al. 1994. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 14:783-801.
26. Eidelberg, D., S. Takikawa, J. R. Moeller et al. 1993. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 33:518-527.
27. Eidelberg, D., V. Dhawan, J. R. Moeller et al. 1991. The metabolic landscape of cortico-basal ganglionic degeneration: Regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry 54:856-862.
28. Fahn, S., D. Oakes, I. Shoulson et al. 2004. Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498-2508.
29. Foster, N. L., S. Gilman, S. Berent et al. 1988. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 24:399-406.
30. Fukuda, M., M. J. Mentis, Y. Ma et al. 2001. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: A PET study of resting-state glucose metabolism. Brain 124:1601-1609.
31. Gaig, C., M. J. Martí, E. Tolosa et al. 2006. [123]I-Ioflupane SPECT in the diagnosis of suspected psychogenic parkinsonism. Mov Disord 21:1994-1998.
32. Geser, F., G. K. Wenning, K. Seppi et al. 2006. Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord 21:179-186.
33. Ghaemi, M., R. Hilker, J. Rudolf et al. 2002. Differentiating multiple system atrophy from Parkinson's disease: Contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 73:517-523.
34. Haapaniemi, T. H., A. Ahonen, P. Torniainen et al. 2001. [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord 16:124-130.
35. Holmes, C., N. Cairns, P. Lantos, and A. Mann. 1999. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 174:45-50.
36. Hosaka, K., K. Ishii, S. Sakamoto et al. 2002. Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration. J Neurol Sci 199:67-71.
37. Hu, X. S., N. Okamura, H. Arai et al. 2000. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 55:1575-1577.
38. Huang, C., C. Tang, A. Feigin et al. 2007. Changes in network activity with the progression of Parkinson's disease. Brain 130:1834-1846.
39. Huang, W. S., S. Z. Lin, J. C. Lin et al. 2001. Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging. J Nucl Med 42:1303-1308.
40. Hughes, A. J., S. E. Daniel, L. Kilford, and A. J. Lees. 1992a. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184.
41. Hughes, A. J., S. E. Daniel, Y. Ben-Shlomo, and A. J. Lees. 2002. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125: 861-870.
42. Hughes, A. J., Y. Ben-Shlomo, S. E. Daniel, and A. J. Lees. 1992. What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study. Neurology 57:S34-38.
43. Jankovic, J., A. H. Rajput, M. P. McDermott, and D. P. Perl. 2000. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol 57:369-372.
44. Juh, R., C.-U. Pae, C.-U. Lee et al. 2005a. Voxel based comparison of glucose metabolism in the differential diagnosis of the multiple system atrophy using statistical parametric mapping. Neurosci Res. 52:211-219.
45. Juh, R., C.-U. Pae, T.-S. Kim et al. 2005b. Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis. Neurosci Lett 383:22-27.
46. Juh, R., J. Kim, D. Moon et al. 2004. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol 51:223-233.
47. Kagi, G., K. P. Bhatia, and E. Tolosa E. 2010. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 81:5-12.
48. Kaplitt, M. G., A. Feigin, C. Tang et al. 2007. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 369:2097-2105.
49. Katzenschlager, R., D. Costa, W. Gerschlager et al. 2003. [123]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor. Ann Neurol 53:489-496.
50. Klaffke, S., A. A. Kuhn, M. Plotkin et al. 2006. Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 21:1724-1727.
51. Lakkegaard, A., L. M. Werdelin, and L. Friberg. 2002. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging 29:1623.
52. Lim, S. M., A. Katsifis, V. L. Villemagne et al. 2009. The 18F-FDG PET cingulate island sign and comparison to 123I-{beta}-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 50:1638-1645.
53. Lin, T. P., M. Carbon, C. Tang et al. 2008. Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. Brain 131:1373-1380.
54. Litvan, I., K. P. Bhatia, D. J. Burn et al. 2003. SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 18:467-486.
55. Lorberboym, M., T. A. Treves, E. Melamed et al. 2006. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 21:510-514.
56. Louis, E. D. 2005. Essential tremor. Lancet Neurol 4:100-110.
57. Louis, E. D., L. S. Honig, J. P. Vonsattel et al. 2005. Essential tremor associated with focal nonnigral Lewy bodies: A clinicopathologic study. Arch Neurol 62:1004-1007.
58. Louis, E. D., P. L. Faust, J. P. Vonsattel et al. 2009. Torpedoes in Parkinson's disease, Alzheimer's disease, essential tremor, and control brains. Mov Disord 24:1600-1605.
59. Louis, E. D., P. L. Faust, J.-P.G. Vonsattel et al. 2007. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain 130:3297-3307.
60. Louis, E. D., S. L. Pullman, D. Eidelberg, and V. Dhawan. 2008. Re-emergent tremor without accompanying rest tremor in Parkinson's disease. Can J Neurol Sci 35:513-515.
61. Ma, Y., C. Tang, P. G. Spetsieris et al. 2007. Abnormal metabolic network activity in Parkinson's disease: Test-retest reproducibility. J Cereb Blood Flow Metab 27:597-605.
62. Marek, K., D. Jennings, and J. Seibyl. 2005. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study. Neurology 64:A274.
63. Marks, W. Jr. J., J. L. Ostrem, L. Verhagen et al. 2008. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Lancet Neurol 7:400-408.
64. McKeith, I. G., D. Galasko, K. Kosaka et al. 1996. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47:1113-1124.
65. McKeith, I. G., D. W. Dickson, J. Lowe et al. 2005. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65:1863-1872.
66. McKeith, I., J. O'Brien, Z. Walker et al. 2007. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: A phase III, multicentre study. Lancet Neurol 6:305-313.
67. McKhann, G., D. Drachman, M. Folstein et al. 1984. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944.
68. Mosconi, L., W. H. Tsui, K. Herholz et al. 2008. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 49:390-398.
69. Nagahama, Y., H. Fukuyama, N. Turjanski et al. 1997. Cerebral glucose metabolism in corticobasal degeneration: Comparison with progressive supranuclear palsy and normal controls. Mov Disord 12:691-696.
70. Neary, D., J. S. Snowden, L. Gustafson et al. 1998. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51:1546-1554.
71. Nelson, P. T., G. A. Jicha, R. J. Kryscio et al. 2010. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 257:359-366.
72. O'Brien, J. T., I. G. McKeith, Z. Walker et al. 2009. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry 194:34-39.
73. O'Brien, J. T., S. Colloby, J. Fenwick et al. 2004. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 61:919-925.
74. O'Sullivan, S. S., L. A. Massey, D. R. Williams et al. 2008. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 131:1362-1372.
75. Otsuka, M., Y. Ichiya, S. Hosokawa et al. 1991. Striatal blood flow, glucose metabolism and 18F-dopa uptake: Difference in Parkinson's disease and atypical parkinsonism. J Neurol Neurosurg Psychiatry 54:898-904.
76. Otsuka, M., Y. Ichiya, Y. Kuwabara et al. 1996. Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson's disease: A positron emission tomographic study. J Neurol Sci 144:77-83.
77. Park, H. K., J. S. Kim, K. C. Im et al. 2009. Functional brain imaging in pure akinesia with gait freezing: FDG PET and FP-CIT PET analyses. Mov Disord 24:237-245.
78. Poston, K. L., E. Rios, and E. D. Louis. 2009. Action tremor of the legs in essential tremor: Prevalence, clinical correlates, and comparison with age-matched controls. Parkinsonism Relat Disord 15:602-605.
79. Rajput, A., C. A. Robinson, and A. H. Rajput. 2004. Essential tremor course and disability: A clinicopathologic study of 20 cases. Neurology 62:932-936.
80. Roman, G. C., T. K. Tatemichi, T. Erkinjuntti et al. 1993. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43:250-260.
81. Schmidt, S. L. P., P. L. Correa, J. C. Tolentino et al. 2008. Value of combining activated brain FDG-PET and cardiac MIBG for the differential diagnosis of dementia: Differentiation of dementia with Lewy bodies and Alzheimer disease when the diagnoses based on clinical and neuroimaging criteria are difficult. Clin Nucl Med 33:398-401.
82. Schneider, S. A., M. J. Edwards, P. Mir et al. 2007. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 22:2210-2215.
83. Schwarz, J., R. Linke, M. Kerner et al. 2000. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: Implications for a preclinical diagnosis. Arch Neurol 57:205-208.
84. Sedaghat, F., A. Gotzamani-Psarrakou, E. Dedousi et al. 2007. Evaluation of dopaminergic function in frontotemporal dementia using I-FP-CIT single photon emission computed tomography. Neurodegener Dis 4:382-385.
85. Shih, L. C., and D. Tarsy. 2007. Deep brain stimulation for the treatment of atypical parkinsonism. Mov Disord 22:2149-2155.
86. Shiryaev, N., Y. Jouroukhin, E. Giladi et al. 2009. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 34:381-388.
87. Spetsieris, P. G., and D. Eidelberg. 2011. Scaled subprofile modeling of resting state imaging data in Parkinson's disease: Methodological issues. NeuroImage 54(4):2899-914.
88. Tang, C. C., K. L. Poston, T. Eckert et al. 2010. Differential diagnosis of parkinsonism: A metabolic imaging study using pattern analysis. Lancet Neurol 9:149-158.
89. Taniwaki, T., M. Nakagawa, T. Yamada et al. 2002. Cerebral metabolic changes in early multiple system atrophy: A PET study. J Neurol Sci 200:79-84.
90. The Parkinson Study Group. 2002. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653-1661.
91. Tinazzi, M., S. Ottaviani, I. U. Isaias et al. 2008. [123I]FP-CIT SPET imaging in drug-induced parkinsonism. Mov Disord 23:1825-1829.
92. Trocello, J.-M., P. Zanotti-Fregonara, E. Roze et al. 2008. Dopaminergic deficit is not the rule in orthostatic tremor. Mov Disord 23:1733-1738.
93. Trost, M., S. Su, P. Su et al. 2006. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage 31:301-307.
94. Van Laere, K., L. De Ceuninck, R. Dom et al. 2004a. Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging 31:1119-1127.
95. Van Laere, K., P. Santens, T. Bosman et al. 2004b. Statistical parametric mapping of 99mTc-ECD SPECT in idiopathic Parkinson's disease and multiple system atrophy with predominant parkinsonian features: Correlation with clinical parameters. J Nucl Med 45:933-942.
96. Varrone, A., M. Pagani, E. Salvatore et al. 2007. Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson's disease. Eur J Nucl Med Mol Imaging 34:1071-1081.
97. Vlaar, A. M., M. J. van Kroonenburgh, A. G. Kessels, and W. E. Weber. 2007. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 7:27.
98. Walker, Z., D. C. Costa, R. W. Walker et al. 2002. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73:134-140.
99. Walker, Z., E. Jaros, R. W. Walker et al. 2007. Dementia with Lewy bodies: A comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 78:1176-1181.
100. Whone, A. L., R. L. Watts, A. J. Stoessl et al. 2003. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54:93-101.
101. Williams, D. R., and A. J. Lees. 2009. Progressive supranuclear palsy: Clinicopathological concepts and diagnostic challenges. Lancet Neurol 8:270-279.
102. Williams, D. R., and A. J. Lees. 2010. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord 25:357-362.
103. Williams, D. R., R. de Silva, D. C. Paviour et al. 2005. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 128:1247-1258.
104. Yong, S. W., J. K. Yoon, Y. S. An, P. H. Lee. 2007. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol 14:1357-1362.